**Listă Lucrări**

Dr. Potre-Oncu Ovidiu-Sebastian

# Teza de doctorat

Factori de prognostic care influențează supraviețuirea în Limfomul Hodgkin. Conducător științific: Prof. Univ. Dr. Ioniță Hortensia

# Selecția celor 10 lucrări considerate cele mai semnificative

1. **Ovidiu Potre**, Monica Pescaru, Alexandra Sima, Ioana Ioniță, Raluca Tudor, Ema Borsi, Miruna Samfireag, Cristina Potre. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience. Medicina, 2021, 57(10), 1026, https://doi.org/10.3390/medicina57101026. FI: 2,430
2. Braha A, Albai A, Timar B, Cipu D, Vasiluta L, **Potre O**, Timar R. Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes. Medicina, 2022, 58(1):21. https://doi.org/10.3390/medicina58010021. FI:2.430
3. Costachescu D, Ionita I, Borsi EC, **Potre O**, Potre C, Navolan DB, Blidisel A, Ionita H, Erimescu A, Pop GN, Malita DC. Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma. Experimental and Therapeutic Medicine, 2021, 22(2):827. DOI: 10.3892/etm.2021.10259. FI: 2.447
4. Borsi E, Serban CL, Potre C, **Potre O**, Putnoky S, Samfireag M, Tudor R, Ionita I, Ionita H. High Carbohydrate Diet Is Associated with Severe Clinical Indicators, but Not with Nutrition Knowledge Score in Patients with Multiple Myeloma. International Journal of Environmental Research and Public Health, 2021, 18(10):5444. DOI: 10.3390/ijerph18105444. FI: 3.39
5. Patrascu R, Albai A, Braha A, Gaita L, Lazar S, **Potre O**, Timar B. Instrument for Assessing Patients' Desirability, Acceptability, and Adherence to Telemedicine in Diabetes: Development, Validity, and Reliability. Patient Preference and Adherence. 2021, 15:2705-2713. DOI: 10.2147/PPA.S343869. FI: 2.711
6. Preda M, Ilina R, **Potre O**, Potre C, Mazilu O. Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics. Cancer Management and Research, 2020, 12: 12447-12455. DOI: 10.2147/CMAR.S278795. FI: 3.989
7. Gaita L, Timar R, Lupascu N, Roman D, Albai A, **Potre O**, Timar B. The Impact Of Hyperuricemia On Cardiometabolic Risk Factors In Patients With Diabetes Mellitus: A Cross-Sectional Study. Diabetes Metabolic Syndrome and Obesity – Targets and Therapy, 2019, 12:2003-2010. DOI: 10.2147/DMSO.S222570. FI:2.842
8. Lupascu N, Timar B, Albai A, Roman D, **Potre O**, Timar R. Validation and cross-cultural adaptation of the depression Patient's Health Questionnaire-9 in the Romanian population of patients with Type 2 Diabetes Mellitus. Diabetes Metabolic Syndrome and Obesity – Targets and Therapy, 2019, 12:841-849. DOI10.2147/DMSO.S203099. FI:2.842
9. Borsi EC, Bucur A, Potre-Oncu C, **Potre-Oncu O**, Cerbu B, Costachescu D, Ionita I, Luca CT, Ionita H. First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone. Revista de Chimie, 2019, 70(3):1017-1022. FI: 1.755
10. Pescaru M, **Potre-Oncu O**, Bucur AI, Ionita H, Popovici RA, Rusu LC, Potre-Oncu C. The Effects of the Therapeutic Regimen Used in Hodgkin Lymphoma and the Correlation with Prognosis Factors. Revista de Chimie, 2018, 69(10): 2868-2873. FI:1.605

# Articole publicate in extenso

## Articole în reviste cotate ISI (Clarivate’s Web of Science), cu factor de impact

1. **Ovidiu Potre**, Monica Pescaru, Alexandra Sima, Ioana Ioniță, Raluca Tudor, Ema Borsi, Miruna Samfireag, Cristina Potre. Evaluation of the Relapse Risk and Survival Rate in Patients with Hodgkin Lymphoma: A Monocentric Experience. Medicina, 2021, 57(10), 1026, https://doi.org/10.3390/medicina57101026. FI: 2,430
2. Braha A, Albai A, Timar B, Cipu D, Vasiluta L, **Potre O**, Timar R. Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes. Medicina, 2022, 58(1):21. https://doi.org/10.3390/medicina58010021. FI:2.430
3. Costachescu D, Ionita I, Borsi EC, **Potre O**, Potre C, Navolan DB, Blidisel A, Ionita H, Erimescu A, Pop GN, Malita DC. Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma. Experimental and Therapeutic Medicine, 2021, 22(2):827. DOI: 10.3892/etm.2021.10259. FI: 2.447
4. Borsi E, Serban CL, Potre C, **Potre O**, Putnoky S, Samfireag M, Tudor R, Ionita I, Ionita H. High Carbohydrate Diet Is Associated with Severe Clinical Indicators, but Not with Nutrition Knowledge Score in Patients with Multiple Myeloma. International Journal of Environmental Research and Public Health, 2021, 18(10):5444. DOI: 10.3390/ijerph18105444. FI: 3.39
5. Patrascu R, Albai A, Braha A, Gaita L, Lazar S, **Potre O**, Timar B. Instrument for Assessing Patients' Desirability, Acceptability, and Adherence to Telemedicine in Diabetes: Development, Validity, and Reliability. Patient Preference and Adherence. 2021, 15:2705-2713. DOI: 10.2147/PPA.S343869. FI: 2.711
6. Preda M, Ilina R, **Potre O**, Potre C, Mazilu O. Survival Analysis of Patients with Inflammatory Breast Cancer in Relation to Clinical and Histopathological Characteristics. Cancer Management and Research, 2020, 12: 12447-12455. DOI10.2147/CMAR.S278795. FI: 3.989
7. Gaita L, Timar R, Lupascu N, Roman D, Albai A, **Potre O**, Timar B. The Impact Of Hyperuricemia On Cardiometabolic Risk Factors In Patients With Diabetes Mellitus: A Cross-Sectional Study. Diabetes Metabolic Syndrome and Obesity – Targets and Therapy, 2019, 12:2003-2010. DOI10.2147/DMSO.S222570. FI:2.842
8. Lupascu N, Timar B, Albai A, Roman D, **Potre O**, Timar R. Validation and cross-cultural adaptation of the depression Patient's Health Questionnaire-9 in the Romanian population of patients with Type 2 Diabetes Mellitus. Diabetes Metabolic Syndrome and Obesity – Targets and Therapy, 2019, 12:841-849. DOI10.2147/DMSO.S203099. FI:2.842
9. Borsi EC, Bucur A, Potre-Oncu C, **Potre-Oncu O**, Cerbu B, Costachescu D, Ionita I, Luca CT, Ionita H. First Line Therapy in Multiple Myeloma: VAD vs Bortezomib -Dexamethasone. Revista de Chimie, 2019, 70(3):1017-1022. FI: 1.755
10. Pescaru M, **Potre-Oncu O**, Bucur AI, Ionita H, Popovici RA, Rusu LC, Potre-Oncu C. The Effects of the Therapeutic Regimen Used in Hodgkin Lymphoma and the Correlation with Prognosis Factors. Revista de Chimie, 2018, 69(10): 2868-2873. FI:1.605
11. Romanescu Sorica C, Bucur AI, **Potre-Oncu O**, Pescaru M, Popovici RA, Ionita I, Ionita HM. The Adverse Effects of Pyrazinoic Acid Phenylalanine in Multiple Myeloma. Revista de Chimie, 2016, 67(8): 1650-1653. FI: 1.232.

## Articole în reviste indexate BDI

1. Potre-Oncu O, Ionita I, Ionita M, Calamar D, Sorica C, Ionita H. Prediction of treatment pancytopenia – prognostic factor in Hodgkin Lymphoma Medicine in Evolution, 2014, 20(2):174-180
2. Potre O, Sorica C, Budai E, Sima R, Trinca B, Pescaru M, Nedelcu M, Toma L. First-line treatment in advanced Hodgkin Lymphoma. Medicine in Evolution, 2014, 20(1):68-74
3. Potre-Oncu O, Ionita I, Ionita M, Calamar D, Sorica C, Ionita H. BCL-2 espression as a negative prognostic factor in Hodgkin Lymphoma, 2014, 24.2(82):43-47
4. Pescaru M, Potre-Oncu C, Bucur AI, Niculescu B, Iurciuc S, Enatescu VR, Ionita H, Boruga MV, Potre-Oncu O. The impact of Complex Treatment, Doxorubicin C27H29NO11, Bleomycin C55H84N17O21S3, Vinblastine C46H58N4O9 and Carabazine C6H10N6O Correlated with Haematological Parameters on Hodgkin’s Lymphoma Survival Prognosis. Revista de Chimie, 2020, 71(7):504-512. https://doi.org/10.37358/RC.20.7.8270.
5. Borsi E, Bucur A, Ionita I, Potre-Oncu C, Potre-Oncu O, Tudor R, Gal-Nadasal EG, Ionita H. Advantages and Drawbacks of Carfilzomib vs. Bortezomib. Revista de Chimie, 2019, 70(12): 4499-4503
6. Albai A, Lupascu N, Popescu S, Timar B, Potre O, Potre C, Timar R. The influence of hyperglycemia on the outcome of diabetic pregnancies. The Romanian Journal of Diabetes, Nutrition and Metabolic Diseases, 2018, 25(2):215-221. doi: 10.2478/rjdnmd-2018-0025
7. Sorica-Romanescu C, Potre O, Bucur A, Ionita I, Pescaru M, Ionita H. Complications of chemotherapy in multiple myeloma. Fiziologia, 2016, 26.2(90):19-22
8. Sorica-Romanescu C, Potre O, Bucur A, Ionita I, Pescaru M, Ionita H. Prognostic factors in the survival of multiple myeloma patients. Medicine in evolution, 2016, 22(2):193-197

# Articole publicate în rezumat

1. Samfireag M, Potre C, Potre O, Pescaru M, Tudor R, Ionita I, Ionita H, Anghel A. Thrombophilic gene mutations as risk factors for recurrent pregnancy loss. European Journal of Human Genetics, 2020, 28(Suppl.1): 626-626. Meeting Abstract: P16.35.B. FI: 4.246
2. Borsi E, Potre C, Potre O, Samfireag M, Ionita I, Ionita H, Larisa-Marina D. Risk evaluation of thrombophilia in pregnancy. European Journal of Human Genetics, 2019, 27(Suppl. 2): 1819-1820. Meeting Abstract: E-P01.17. FI:4.246
3. Potre O, Borsi E, Pescaru M, Samfireag M, Potre C. The impact of mutations in patients diagnosed with myelofibrosis secondary to policytemia vera or essential thrombocytemia. Revista Romana de Medicina de Laborator, 2019, 27(1)
4. Potre C, Borsi E, Pescaru M, Samfireag M, Potre O. The evolution and prognosis of patients diagnosed with low risk mielodysplastic sydrome with DEL (5Q). Revista Romana de Medicina de Laborator, 2019, 27(1)
5. Borsi EC, Potre C, Potre O, Samfireag M, Ionita I, Ionita H. The role of cytogenetic factors for multiple myeloma patients. Revista Romana de Medicina de Laborator, 2019, 27(1)
6. Samfireag MA, Potre C, Potre O, Borsi EC, Pescaru M, Ionita I, Ionita H, Anghel A. Vitamin B12, prognostic factor in myelodisplastic syndromes. Revista Romana de Medicina de Laborator, 2019, 27(1)